Email this article Efficiency and safety of the everolimus in patients with the generalized renal cell carcinoma (multicentral observational study)
- Authors: Volkova M.I.1,2, Nosov D.A.1,2, Chernyaev V.A.1,2, Voroshilova E.A.1,2, Sayapina M.S.1,2, Kolesnikov G.P.3,4, Leonenkov R.V.5,6, Khvorostenko D.A.7,8, Borisov P.S.9,10, Shushakov M.U.11,12, Kirdakova N.V.13,14, Alekseev B.Y.15,16, Matyash M.G.17,18
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- 23 Kashirskoe Shosse, Moscow, 115478, Russia
- Outpatient Department of the Moscow Municipal Oncological Hospital № 62 of Moscow Healthcare Department
- 6 Staropetrovskiy Proezd, Moscow, 125130, Russia
- St. Petersburg Clinical Research and Practical Center of Specialized Types of Medical Care (Oncologic)
- 68a Leningradskaya St., township Pesochnyy, Saint Petersburg, 197758, Russia
- Leningrad Regional Oncology Dispensary
- 37 Liteynyy Prospekt, Saint Petersburg, 191014, Russia
- City Clinical Oncology Dispensary
- 3/5 Second Berezovaya Avenue, Saint Petersburg, 197022, Russia
- Municipal Polyclinic № 11, filial № 4
- 5 Novatorov St., Moscow, 119421, Russia
- Clinical Oncology Dispensary № 1 of Moscow Healthcare Department
- 17/1 Baumanskaya St., Moscow, 105005, Russia
- P.A. Herzen Moscow Oncology Research Institute Ministry of Health of Russia
- 3nd Botkinskiy Passage, Moscow, 125284, Russia
- Novartis, Department of the Oncological Agents
- Moscow, Russia
- Issue: Vol 12, No 2 (2016)
- Pages: 18-27
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.06.2016
- URL: https://oncourology.abvpress.ru/oncur/article/view/571
- DOI: https://doi.org/10.17650/1726-9776-2016-12-2-18-27
- ID: 571
Cite item
Abstract
Objective – to evaluate efficacy and safety of everolimus in Russian population of unselected patients with advanced renal cell carcinoma progressing after at least 1 line of anti-angiogenic targeted therapy.
Materials and methods. In observational multicenter study CRAD001LRU03 from 17.01.2012 to 31.03.2015 in 43 centers 226 patients with advanced renal cell carcinoma with documented progression on the background or after at least 1 line of anti-angiogenic targeted therapy were included. The survey was conducted on all patients according to the practice, everolimus therapy was administered in accordance with instructions to the drug.
Results. Objective response rate was 10 %, tumor control was achieved on 69.2 % of patients. Progression-free survival median – 7.8 months. Adverse events occurred in 44.7 % of patients, reached the III–IV severity of 9.3 %, were the reason for the cancellation of everolimus therapy in 2.2 % of cases. The most frequent complications of treatment were pneumonitis (n = 5 (2.2 %)) and anemia (n = 3 (1.3 %)).
Conclusion. The observational study confirms efficacy and favorable safety profile of everolimus mTOR inhibitor in the Russian unselected patients with advanced renal cell carcinoma with progression or intolerable toxicity against background of anti-angiogenic therapy.
About the authors
M. I. Volkova
N.N. Blokhin Russian Cancer Research Center; 23 Kashirskoe Shosse, Moscow, 115478, Russia
Author for correspondence.
Email: mivolkova@rambler.ru
Russian Federation
D. A. Nosov
N.N. Blokhin Russian Cancer Research Center; 23 Kashirskoe Shosse, Moscow, 115478, RussiaRussian Federation
V. A. Chernyaev
N.N. Blokhin Russian Cancer Research Center; 23 Kashirskoe Shosse, Moscow, 115478, RussiaRussian Federation
E. A. Voroshilova
N.N. Blokhin Russian Cancer Research Center; 23 Kashirskoe Shosse, Moscow, 115478, RussiaRussian Federation
M. S. Sayapina
N.N. Blokhin Russian Cancer Research Center; 23 Kashirskoe Shosse, Moscow, 115478, RussiaRussian Federation
G. P. Kolesnikov
Outpatient Department of the Moscow Municipal Oncological Hospital № 62 of Moscow Healthcare Department; 6 Staropetrovskiy Proezd, Moscow, 125130, RussiaRussian Federation
R. V. Leonenkov
St. Petersburg Clinical Research and Practical Center of Specialized Types of Medical Care (Oncologic); 68a Leningradskaya St., township Pesochnyy, Saint Petersburg, 197758, RussiaRussian Federation
D. A. Khvorostenko
Leningrad Regional Oncology Dispensary; 37 Liteynyy Prospekt, Saint Petersburg, 191014, RussiaRussian Federation
P. S. Borisov
City Clinical Oncology Dispensary; 3/5 Second Berezovaya Avenue, Saint Petersburg, 197022, RussiaRussian Federation
M. U. Shushakov
Municipal Polyclinic № 11, filial № 4; 5 Novatorov St., Moscow, 119421, RussiaRussian Federation
N. V. Kirdakova
Clinical Oncology Dispensary № 1 of Moscow Healthcare Department; 17/1 Baumanskaya St., Moscow, 105005, RussiaRussian Federation
B. Ya. Alekseev
P.A. Herzen Moscow Oncology Research Institute Ministry of Health of Russia; 3nd Botkinskiy Passage, Moscow, 125284, RussiaRussian Federation
M. G. Matyash
Novartis, Department of the Oncological Agents; Moscow, RussiaRussian Federation
References
Supplementary files
